Hypertension and microvascular remodelling

Cardiovascular Research

Volumn 78, Issue 2, 2008, Pages 274-285

  Feihl, François ^a   Liaudet, Lucas ^b   Levy, Bernard I ^c   Waeber, Bernard ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Hypertension; Microcirculation; Resistance artery; Structure

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ATENOLOL; CANDESARTAN; ENALAPRIL; INTEGRIN; IRBESARTAN; LOSARTAN; NITRIC OXIDE; PERINDOPRIL; REACTIVE OXYGEN METABOLITE; VALSARTAN;

ADVENTITIA; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CYTOSKELETON; EXTRACELLULAR MATRIX; HEREDITY; HUMAN; HYPERTENSION; HYPOTHESIS; MICROVASCULATURE; NOMENCLATURE; NONHUMAN; PATHOPHYSIOLOGY; PRESSORECEPTOR; PRIORITY JOURNAL; PROGNOSIS; RESISTANCE BLOOD VESSEL; REVIEW; SYMPATHETIC TONE; TISSUE REPAIR;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; HYPERPLASIA; HYPERTENSION; MECHANOTRANSDUCTION, CELLULAR; MICROCIRCULATION; MODELS, CARDIOVASCULAR; STRESS, MECHANICAL; TERMINOLOGY AS TOPIC; VASCULAR RESISTANCE;

EID: 42349107378     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn022     Document Type: Review

References (119)

1. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension, a disease of the microcirculation? Hypertension 2006;48:1012-1017.
2. Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hosp Rep 1836;1:338-379.
3. Bright R. Tabular view of the morbid appearances in 100 cases connected with albuminous urine, with observations. Guy's Hosp Rep 1836;1:380-400.
4. Johnson GI. On certain points in the pathology of Bright's disease of the kidney. II. On the influence of the minute blood vessels upon the circulation. Tr Medico-Chir Soc Lond 1868;51:57-76.
5. Ewald CA. Ueber die Veränderungen kleiner Gefässe bei Morbus Brightii und die darauf bezüglichen Theorien. Virchows Arch 1877;71:453-499.
6. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.
7. Newton NM, Fine LG. Inference of the existence of high blood pressure as a cause of renal disease in the mid-19th century: observations on vascular structures in the kidney. Am J Nephrol 1999;19:323-332.
8. Kernohan JW, Anderson EW, Keith NM. The arterioles in cases of hypertension. Arch Intern Med 1929;44:395-423.
9. Folkow B. The 'structural factor' in hypertension, with special emphasis on the hypertrophic adaptation of the systemic resistnace vessels. In: Laragh JH, Brenner BM (ed.), Hypertension: Pathophysiology, Diagnosis and Treatment. New York, Raven Press, Ltd; 1990. p565-581.
10. Folkow B, Grimby G, Thuslesius O. Adaptive structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand 1958;44:255-272.
11. Mulvany MJ, Hansen OK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 1978;43:854-864.
12. Schiffrin EL, Deng LY, Larochelle P. Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med 1993;16:177-186.
13. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti-Rosei E. Vascular structural and functional alterations before and after the development of hypertension in SHR. Am J Hypertens 1994;7:193-200.
14. Rosei EA, Rizzoni D, Castellano M, Porteri E, Zulli R, Muiesan ML et al. Media: lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. J Hypertens 1995;13:341-347.
15. Christensen KL, Mulvany MJ. Location of resistance arteries. J Vasc Res 2001;38:1-12.
16. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HAJ. Microcirculation in hypertension - a new target for treatment? Circulation 2001;104:735-740.
17. Davis MJ. Myogenic response gradient in an arteriolar network. Am J Physiol 1993;264:H2168-H2179.
18. Glagov S, Vito R, Giddens DP, Zarins CK. Micro-architecture and composition of artery walls: relationship to location, diameter and the distribution of mechanical stress. J Hypertens Suppl 1992;10:S101- S104.
19. Dilley RJ, McGeachie JK, Prendergast FJ. A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia. Arch Surg 1988;123:691-696.
20. Korner PI, Angus JA. Vascular remodeling. Hypertension 1997;29:1065-1066.
21. Mulvany MJ. Small artery remodeling in hypertension. Curr Hypertens Rep 2002;4:49-55.
22. Simon G. Pathogenesis of structural vascular changes in hypertension. J Hypertens 2004;22:3-10.
23. Mulvany MJ. Small artery structure: time to take note? Am J Hypertension 2007;20:853-854.
24. Lehoux S, Tedgui A. Cellular mechanics and gene expression in blood vessels. J Biomech 2003;36:631-643.
25. Pries AR, Reglin B, Secomb TW. Structural adaptation of vascular networks: role of the pressure response. Hypertension 2001;38:1476-1479.
26. Nichols WW, O'Rourke MF. Chap. 2: The nature of flow of a fluid. McDonald's blood flow in arteries. London, Edward Arnold; 1990. p12-53.
27. Pries AR, Reglin B, Secomb TW. Remodeling of blood vessels: responses of diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension 2005;46:725-731.
28. Short D. Morphology of the intestinal arterioles in chronic human hypertension. Br Heart J 1966;28:184-192.
29. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989;13:968-972.
30. Mulvany MJ. Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res 1999;41:9-13.
31. Bund SJ, Lee RM. Arterial structural changes in hypertension: a consideration of methodology, terminology and functional consequence. J Vasc Res 2003;40:547-557.
32. Mulvany MJ. Structural abnormalities of the resistance vasculature in hypertension. J Vasc Res 2003;40:558-560.
33. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 1993;21:391-397.
34. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990;70:921-961.
35. St Lezin E, Simonet L, Pravenec M, Kurtz TW. Hypertensive strains and normotensive 'control' strains. How closely are they related? Hypertension 1992;19:419-424.
36. Thybo NK, Korsgaard N, Mulvany MJ. Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension. J Hypertens 1992;10:1191-1196.
37. Struijker-Boudier HA, van Essen H, Fazzi G, De Mey JG, Qiu HY, Levy BI. Disproportional arterial hypertrophy in hypertensive mRen-2 transgenic rats. Hypertension 1996;28:779-784.
38. Dunn WR, Gardiner SM. Differential alteration in vascular structure of resistance arteries isolated from the cerebral and mesenteric vascular beds of transgenic [(mRen-2)27], hypertensive rats. Hypertension 1997;29:1140-1147.
39. Heerkens EH, Shaw L, Ryding A, Brooker G, Mullins JJ, Austin C et al. AlphaV integrins are necessary for eutrophic inward remodeling of small arteries in hypertension. Hypertension 2006;47:281-287.
40. Hashimoto H, Prewitt RL, Efaw CW. Alterations in the microvasculature of one-kidney, one-clip hypertensive rats. Am J Physiol 1987;253: H933-H940.
41. Korsgaard N, Mulvany MJ. Cellular hypertrophy in mesenteric resistance vessels from renal hypertensive rats. Hypertension 1988;12:162- 167.
42. Stacy DL, Prewitt RL. Effects of chronic hypertension and its reversal on arteries and arterioles. Circ Res 1989;65:869-879.
43. Lee RM. Structural alterations of blood vessels in hypertensive rats. Canad J Physiol Pharmacol 1987;65:1528-1535.
44. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626-635.
45. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995;26:957-962.
46. Miller BG, Connors BA, Bohlen HG, Evan AP. Cell and wall morphology of intestinal arterioles from 4- to 6- and 17- to 19-week-old Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 1987;9:59-68.
47. Owens GK, Schwartz SM, McCanna M. Evaluation of medial hypertrophy in resistance vessels of spontaneously hypertensive rats. Hypertension 1988;11:198-207.
48. Smeda JS, Lee RM, Forrest JB. Structural and reactivity alterations of the renal vasculature of spontaneously hypertensive rats prior to and during established hypertension. Circ Res 1988;63:518-533.
49. Dunn WR, Wallis SJ, Gardiner SM. Remodelling and enhanced myogenic tone in cerebral resistance arteries isolated from genetically hypertensive Brattleboro rats. J Vasc Res 1998;35:18-26.
50. Bund SJ. Spontaneously hypertensive rat resistance artery structure related to myogenic and mechanical properties. Clin Sci 2001;101:385-393.
51. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999;33:569-574.
52. Amann K, Gharehbaghi H, Stephen S, Mall G. Hypertrophy and hyperplasia of smooth muscle cells of small intramyocardial arteries in spontaneously hypertensive rats. Hypertension 1995;25:124-131.
53. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996;28:785-790.
54. Rizzoni D, Porteri E, Guefi D, Piccoli A, Castellano M, Pasini G et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000;35:931-935.
55. Rizzoni D, Porteri E, Boari GE, De Ciuceis C, Sleiman I, Muiesan ML et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003;108:2230-2235.
56. Mathiassen ON, Buus NH, Sihm I, Thybo NK, Morn B, Schroeder AP et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007;25:1021-1026.
57. De Ciuceis C, Porteri E, Rizzoni D, Rizzardi N, Paiardi S, Boari GE et al. Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertension 2007;20:846-852.
58. Rizzoni D, Muiesan ML, Porteri E, Castellano M, Zulli R, Bettoni G et al. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997;15:197-204.
59. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001;103:1238-1244.
60. Aalkjaer C, Heagerty AM, Bailey I, Mulvany MJ, Swales JD. Studies of isolated resistance vessels from offspring of essential hypertensive patients. Hypertension 1987;9:III155-III158.
61. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987;61:181-186.
62. Korsgaard N, Aalkjaer C, Heagerty AM, Izzard AS, Mulvany MJ. Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993;22:523-526.
63. Izzard AS, Cragoe EJ Jr, Heagerty AM. Intracellular pH in human resistance arteries in essential hypertension. Hypertension 1991;17:780-786.
64. Thurmann PA, Stephens N, Heagerty AM, Kenedi P, Weidinger G, Rietbrock N. Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Hypertension 1996;28:450-456.
65. Endemann DH, Pu Q, De Ciuceis C, Savoia C, Virdis A, Neves MF et al. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. Hypertension 2004;43:399-404.
66. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002;106:3037-3043.
67. Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002;20:1439-1444.
68. Kvist S, Mulvany MJ. Reduced medication and normalization of vascular structure, but continued hypertension in renovascular patients after revascularization. Cardiovasc Res 2001;52:136-142.
69. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996;14:1247-1255.
70. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659.
71. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001;19:921-930.
72. Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozakova M, La Canna G et al. Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J Hypertens 2003;21:625-631.
73. Harazny JM, Ritt M, Baleanu D, Ott C, Heckmann J, Schlaich MP et al. Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. Hypertension 2007;50:623-629.
74. Lee RM. Vascular changes at the prehypertensive phase in the mesenteric arteries from spontaneously hypertensive rats. Blood Vessels 1985;22:105-126.
75. Takeshita A, Imaizumi T, Ashihara T, Yamamoto K, Hoka S, Nakamura M. Limited maximal vasodilator capacity of forearm resistance vessels in normotensive young men with a familial predisposition to hypertension. Circ Res 1982;50:671-677.
76. Giannattasio C, Cattaneo BM, Mangoni AA, Carugo S, Stella ML, Failla M et al. Cardiac and vascular structural changes in normotensive subjects with parental hypertension. J Hypertens 1995;13:259-264.
77. Folkow B, Gurevich M, Hallback M, Lundgren Y, Weiss L. The hemodynamic consequences of regional hypotension in spontaneously hypertensive and normotensive rats. Acta Physiol Scand 1971;83:532-541.
78. Bund SJ, West KP, Heagerty AM. Effects of protection from pressure on resistance artery morphology and reactivity in spontaneously hypertensive and Wistar-Kyoto rats. Circ Res 1991;68:1230-1240.
79. Stacy DL, Prewitt RL. Attenuated microvascular alterations in coarctation hypertension. Am J Physiol 1989;256:H213-H221.
80. Heerkens EH, Izzard AS, Heagerty AM. Integrins vascular remodeling hypertension. Hypertension 2007;49:1-4.
81. Martinez-Lemus LA, Hill MA, Bolz SS, Pohl U, Meininger GA. Acute mechanoadaptation of vascular smooth muscle cells in response to continuous arteriolar vasoconstriction: implications for functional remodeling. FASEB J 2004;18:708-710.
82. Bakker EN, van der Meulen ET, van den Berg BM, Everts V, Spaan JA, VanBavel E. Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J Vasc Res 2002;39:12-20.
83. Safar ME, Lacolley P. Disturbance of macro- and microcirculation: relations with pulse pressure and cardiac organ damage. Am J Physiol 2007;293:H1-H7.
84. Lehoux S, Esposito B, Merval R, Tedgui A. Differential regulation of vascular focal adhesion kinase by steady stretch and pulsatility. Circulation 2005;111:643-649.
85. Plunkett WC, Overbeck HW. Increased arteriolar wall-to-lumen ratio in a normotensive vascular bed in coarctation hypertension. Am J Physiol 1985;249:H859-H866.
86. Liu JL, Bishop SP, Overbeck HW. Morphometric evidence for non-pressure-related arterial wall thickening in hypertension. Circ Res 1988;62:1001-1010.
87. O'Callaghan CJ, Williams B. The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation. J Hypertens 2002;20:287-294.
88. August P, Suthanthiran M. Transforming growth factor beta signaling, vascular remodeling, and hypertension. N Engl J Med 2006;354:2721- 2723.
89. Lee RM, Borkowski KR, Leenen FH, Tsoporis J, Coughlin M. Combined effect of neonatal sympathectomy and adrenal demedullation on blood pressure and vascular changes in spontaneously hypertensive rats. Circ Res 1991;69:714-721.
90. Simon G, Csiky B. Effect of neonatal sympathectomy on the development of structural vascular changes in angiotensin II-treated rats. J Hypertens 1998;16:77-84.
91. Porteri E, Rizzoni D, Mulvany MJ, De Ciuceis C, Sleiman I, Boari GE et al. Adrenergic mechanisms and remodeling of subcutaneous small resistance arteries in humans. J Human Hypertens 2003;21:2345-2352.
92. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005;90:449-455.
93. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007;27:297-302.
94. Touyz RM, He G, Wu XH, Park JB, Mabrouk ME, Schiffrin EL. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension 2001;38:56-64.
95. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001;38:581- 587.
96. Fortuno A, Jose GS, Moreno MU, Diez J, Zalba G. Oxidative stress and vascular remodelling. Exp Physiol 2005;90:457-462.
97. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998;32:488-495.
98. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001;19:1245-1254.
99. Marin E, Sessa WC. Role of endothelial-derived nitric oxide in hypertension and renal disease. Curr Opin Nephrol Hypertens 2007;16:105-110.
100. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731-736.
101. de Jongh RT, Serne EH, Ijzerman RG, Stehouwer CD. Microvascular function: a potential link between salt sensitivity, insulin resistance and hypertension. J Hypertens 2007;25:1887-1893.
102. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-1032.
103. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68.
104. Martinez-Lemus LA, Crow T, Davis MJ, Meininger GA. Alphavbeta3- and alpha5beta1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles. Am J Physiol 2005;289:H322-H329.
105. Bakker EN, Buus CL, VanBavel E, Mulvany MJ. Activation of resistance arteries with endothelin-1: from vasoconstriction to functional adaptation and remodeling. J Vasc Res 2004;41:174-182.
106. Siow RC, Churchman AT. Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in. Cardiovasc Res 2007;75:659-668.
107. Siow RC, Mallawaarachchi CM, Weissberg PL. Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries. Cardiovasc Res 2003;59:212-221.
108. Arribas SM, Gonzalez C, Graham D, Dominiczak AF, McGrath JC. Cellular changes induced by chronic nitric oxide inhibition in intact rat basilar arteries revealed by confocal microscopy. J Hypertens 1997;15:1685-1693.
109. Arribas SM, Hillier C, Gonzalez C, McGrory S, Dominiczak AF, McGrath JC. Cellular aspects of vascular remodeling in hypertension revealed by confocal microscopy. Hypertension 1997;30:1455-1464.
110. McGrath JC, Deighan C, Briones AM, Shafaroudi MM, McBride M, Adler J et al. New aspects of vascular remodelling: the involvement of all vascular cell types. Exp Physiol 2005;90:469-475.
111. Christensen KL, Mulvany MJ. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001;19:1001-1006.
112. Mathiassen ON, Buus NH, Larsen ML, Mulvany MJ, Christensen KL. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. J Hypertens 2007;25:1027-1034.
113. Touyz RM. Vascular remodeling, retinal arteries, and hypertension. Hypertension 2007;50:603-604.
114. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991;69:107-115.
115. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004;44:465-470.
116. Gomez-Garre D, Martin-Ventura JL, Granados R, Sancho T, Torres R, Ruano M et al. Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients. Kidney Int 2006;69:1237-1244.
117. Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006;48:271-277.
118. Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005;45:659-665.
119. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002;20:71-78.